23459-36-1

Basic information

• Product Name: cyclopentyl(phenyl)methanamine
• Synonyms: cyclopentyl(phenyl)methanamine;a-Cyclopentyl-benzeneMethanaMine;C-Cyclopentyl-C-phenyl-methylamine;Cyclopentyl(phenyl)
• CAS NO: 23459-36-1
• Molecular Formula: C₁₂H₁₇N
• Molecular Weight: 175.27008
• Mol File: 23459-36-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 274.8±9.0 °C(Predicted)
• Appearance: /
• Density: 1.022±0.06 g/cm3(Predicted)
• PKA: 9.36±0.10(Predicted)
• CAS DataBase Reference: cyclopentyl(phenyl)methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: cyclopentyl(phenyl)methanamine(23459-36-1)
• EPA Substance Registry System: cyclopentyl(phenyl)methanamine(23459-36-1)

Safety Data

• Hazardous Substances Data: 23459-36-1(Hazardous Substances Data)

Usage

General Description

Cyclopentyl(phenyl)methanamine, also known as CPMA, is an organic compound with the chemical formula C12H17N. It is a derivative of amphetamine and has stimulant effects on the central nervous system. CPMA has been studied for its potential use as a psychoactive substance and has been found to have similar effects to amphetamine, including increased energy and euphoria. The compound is not widely researched and its long-term effects on the human body are not well understood. However, there is evidence to suggest that CPMA may have potential for abuse and addiction due to its stimulant properties. As such, it is a controlled substance in many jurisdictions and its use is highly regulated.

Upstream product

• 110480-94-9 cyclopentylphenylmethanol 
• 151-50-8 potassium cyanide 
• 83568-09-6 cyclopentyl phenyl ketoxime 
• 5422-88-8 phenyl cyclopentyl ketone 
• 77287-34-4 formamide 
• 93141-99-2 syn-Cyclopentyl-phenyl-keton-(O-2-dimethylamino-aethyl-oxim) 
• 790201-65-9 N-(cyclopentyl(phenyl)methyl)formamide 
• 4524-93-0 Cyclopentanecarboxylic acid chloride 
• 3400-45-1 cyclopentanecarboxylic acid 
• 100-47-0 benzonitrile 
• 33240-34-5 cyclopentylmagnesium bromide 
• 100-46-9 benzylamine 

Downstream Products

• 439287-36-2 2-[(cyclopentyl-phenyl-methyl)-carbamoyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 144983-34-6 1-(2-phenylbenzoxazol-7-yl)-3-[(1-phenylcyclopentyl)methyl]urea 
• 326894-43-3 (-)-(S)-N-(cyclopentylphenylmethyl)acetamide 

Relevant articles and documents

Transition-Metal-Free C(sp3)a'H Coupling of Cycloalkanes Enabled by Single-Electron Transfer and Hydrogen Atom Transfer

Here we report a unique transition-metal-free C(sp3)-H/C(sp3)-H coupling of cycloalkanes at room temperature. Unactivated cycloalkanes and 2-azaallyls underwent the combination process of single-electron transfer (SET) and hydrogen atom transfer (HAT) to deliver a wide variety of cycloalkane-functionalized products. This expedient approach enables C(sp3)-H/C(sp3)-H coupling of cycloalkanes under mild conditions without transition metals, initiators, and oxidants.

Method for synthesizing medical intermediates

The invention discloses a method for synthesizing medical intermediates R-alpha-cyclopentyl (phenyl) methylamine. The particular method includes generating racemization alpha-cyclopentyl (phenyl) methylamine from phenyl cyclopentanone by means of reductiv

Synthesis and structure-activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores

Using N-(2,6-dimethyl)phenyl-2-piperidinecarboxamide (1) and N-(α-methylbenzyl)-2-piperidinecarboxamide (2) as structural leads, a variety of analogues were synthesised and evaluated for anticonvulsant activity in the MES test in mice. In the N-benzyl series, introduction of 3-Cl, 4-Cl, 3,4-Cl2, or 3-CF3 groups on the aromatic ring led to an increase in MES activity. Replacement of the α-methyl group by either i-Pr or benzyl groups enhanced MES activity with no increase in neurotoxicity. Substitution on the piperidine ring nitrogen led to a decrease in MES activity and neurotoxicity, while reduction of the amide carbonyl led to a complete loss of activity. Movement of the carboxamide group to either the 3- or 4-positions of the piperidine ring decreased MES activity and neurotoxicity. Incorporation of the piperidine ring into a tetrahydroisoquinoline or diazahydrinone nucleus led to increased neurotoxicity. In the N-(2,6-dimethyl)phenyl series, opening of the piperidine ring between the 1- and 6-positions gave the active norleucine derivative 75 (ED50 = 5.8 mg kg-1, TD50 = 36.4 mg kg-1, PI = 6.3). Replacement of the piperidine ring of 1 by cycloalkane (cyclohexane, cyclopentane, and cyclobutane) resulted in compounds with decreased MES activity and neurotoxicity, whereas replacement of the piperidine ring by a 4-pyridyl group led to a retention of MES activity with a comparable PI. Simplification of the 2-piperidinecarboxamide nucleus of 1 into a glycinecarboxamide nucleus led to about a six-fold decrease in MES activity. The 2,6-dimethylanilides were the most potent compounds in the MES test in each group of compounds evaluated, and compounds 50 and 75 should be useful leads in the development of agents for the treatment of tonic-clonic and partial seizures in man.